Recently, Sinovac Biotech Co., Ltd. (hereinafter referred to as "Sinovac Biotech") and Chengdu Beite Pharmaceutical Co., Ltd. (hereinafter referred to as "Beite Pharmaceutical") signed an intention agreement, intending to achieve overseas commercial strategic cooperation for some of Beite Pharmaceutical's formulation products.

Both parties plan to adopt various cooperation models, including but not limited to overseas commercialization rights for specific products and regions, localized technology transfer in overseas markets, and cooperative development. According to the list of products that can be cooperated with provided by Beite Pharmaceutical, after both parties sign a formal cooperation agreement, Sinopharm will have the commercial cooperation rights of the products in the designated overseas regions.

Beite Pharmaceutical is a high-tech enterprise specializing in pharmaceutical innovation and the R&D, production and sales of high-quality drugs. It has long been committed to the four major R&D directions of characteristic APIs, high-end generic drugs, innovative drugs and new drug delivery systems, and has realized the whole ecological pharmaceutical industry chain layout covering chemical drugs (including nuclide drugs), biological drugs and traditional Chinese patent medicines and simple preparations from intermediates, APIs to preparations. There are over 200 varieties of formulations available for sale, covering multiple key areas such as oncology and immunology, respiration, blood, obstetrics and gynecology, anti infection, imaging, cardiovascular and cerebrovascular diseases, muscle and skeletal systems, and mental and nervous systems.

Sinopharm started exporting its drugs around 2000 and has accumulated over 20 years of experience in overseas commercialization. Its marketing channels cover more than 70 countries and regions worldwide. The company is creating a platform based development model of "global product selection+global coverage", focusing on fields such as anti-tumor, self immunity, metabolism, etc., actively expanding domestic and foreign partners, and quickly seizing overseas markets with a richer product portfolio to provide more treatment options for overseas patients.

This collaboration between Sinopharm and Beite Pharmaceutical to explore opportunities and space for overseas market development is an important step for both parties to jointly enter the global pharmaceutical market. In the future, both sides will continue to deepen cooperation and promote high-quality domestic drugs to go international. (Tan Pengpeng)